Table of Contents
COPENHAGEN / PARSIPPANY, NJ — Novo Nordisk announced Monday the commercial launch of Wegravy, a semaglutide-based table condiment described in the company’s press release as “a paradigm-shifting, full-flavor GLP-1 receptor agonist delivery system in a delicious, pourable format,” available immediately in Beef and Garlic Roasted Chicken, with a Turkey, Sage, & Stuffing variety available November 1. Country White Sausage and vegan-friendly Creamy Mushroom SKUs will follow pending FDA clearance.
The product is launching with a wide array of restaurant and grocery partners including Cracker Barrel, KFC, Denny’s, Albertsons, and Kroger. A limited-edition holiday tin will be available exclusively at Walmart later this year.
Shares of Novo Nordisk rose 11% on the news. KFC, whose gravy-based menu infrastructure analysts described as “the perfect distribution ecosystem,” saw its parent company Yum! Brands gain 4% by midday trading.
“Americans consume approximately 3.2 billion pounds of gravy annually,” said Novo Nordisk Chief Commercial Officer Mette Fired-Bjørnsen in a prepared statement. “We asked ourselves: what if that worked for us instead of against us?”
The move addresses what Novo Nordisk’s internal research identified as a “patient compliance gap” — specifically, that Americans prescribed Wegovy were significantly less likely to self-administer a weekly injection than to consume gravy. The company described the reformulation as “optimizing for America’s preferred drug delivery mechanism.” “The data was not subtle,” Fired-Bjørnsen said.
The gravy is shelf-stable, requires no refrigeration, delivers a 0.5mg semaglutide dose per quarter-cup serving, and pairs equally well with biscuits or mashed potatoes. The recommended weekly intake can be achieved, the company noted, by consuming one Cracker Barrel breakfast.
Cracker Barrel confirmed it will offer Wegravy as a standard substitution on its Old Timer’s Breakfast, Grandpa’s Country Fried Breakfast, and Biscuits n’ Gravy, which the chain described in a joint press release as “a natural fit.”
Heinz, which was not part of the original announcement, issued a statement saying it was “actively in conversations” with Novo Nordisk and had “strong feelings about a squeeze bottle format.”
The announcement drew immediate criticism from former heroin addict and current raw milk enthusiast Robert F. Kennedy Jr., who called the product “unhealthy” and “exactly what I’ve been talking about.” The Health and Human Services Secretary’s staff, when granted anonymity, said he had not been talking about it.
Kennedy later issued a second statement saying he remained opposed to “gravy in general” and was investigating whether the Mushroom variety contained psychoactive compounds, which it allegedly does not.
The Cheesecake Factory and McDonald’s each confirmed they are in active licensing discussions. A Cheesecake Factory spokesperson said the chain was “particularly interested” in Wegravy’s applications, as 87% of the items on its 21-page menu contain gravy or “gravy-adjacent” products. McDonald’s, which has emerged as an industry leader in drug-infused food products following its widely covered Zoloft Happy Meal initiative, confirmed it is in the final testing stages of its long-rumored “McGLP” sandwich and described “McDisco Fries n’ Wegravy” as “a logical next step.”
Wegravy will retail for $14.99 for a 12 oz. jar, or $389 without insurance.
